NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/28/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.06 mln
Float3.80 mln
Earnings Date09/10/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
26.00
Transformational upside
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-264
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alzamend Neuro is an Atlanta-based company, founded in 2016, that is developing new medical treatments for brain-related conditions such as Alzheimer's disease, bipolar disorder, PTSD, and major depression. Its lead treatment, AL001, combines lithium, proline, and salicylate into a single therapy, while its second program, ALZN002, works by training the body's own immune system to fight Alzheimer's disease. Both treatments are currently being tested in clinical trials.
